{"brief_title": "CPG 7909 in Patients With Cutaneous T-Cell Lymphoma", "brief_summary": "To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.", "condition": ["Lymphoma, T-Cell, Cutaneous"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["PF-3512676", "PF-3512676", "PF-3512676", "PF-3512676", "PF-3512676", "PF-3512676", "PF-3512676", "PF-3512676"], "description": ["Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", "Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks."], "arm_group_label": ["Phase I: 0.08 mg/kg", "Phase I: 0.16 mg/kg", "Phase I: 0.24 mg/kg", "Phase I: 0.28 mg/kg", "Phase I: 0.32 mg/kg", "Phase I: 0.36 mg/kg", "Phase II: 10 mg", "Phase II: 25 mg"], "other_name": ["ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909", "ProMune, CPG 7909"], "criteria": "Inclusion Criteria: Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one and no more than 3 systemic treatments. Exclusion Criteria: Patients with visceral involvement, serious infection or illness including human immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) < 60 will be excluded.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "immunotherapy, lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, T-Cell", "Lymphoma, T-Cell, Cutaneous"], "id": "NCT00043420"}